

Joachim Sieper

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7317380/publications.pdf>

Version: 2024-02-01

259
papers

29,130
citations

5248

83
h-index

5364

164
g-index

265
all docs

265
docs citations

265
times ranked

12304
citing authors

#	ARTICLE	IF	CITATIONS
1	What low back pain is and why we need to pay attention. <i>Lancet, The</i> , 2018, 391, 2356-2367.	6.3	2,444
2	Ankylosing spondylitis. <i>Lancet, The</i> , 2007, 369, 1379-1390.	6.3	1,558
3	Axial spondyloarthritis. <i>Lancet, The</i> , 2017, 390, 73-84.	6.3	876
4	Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. <i>Arthritis and Rheumatism</i> , 1998, 41, 58-67.	6.7	854
5	Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. <i>New England Journal of Medicine</i> , 2015, 373, 2534-2548.	13.9	803
6	Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT). <i>Arthritis and Rheumatism</i> , 2005, 52, 582-591.	6.7	773
7	Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2006, 54, 2136-2146.	6.7	768
8	The early disease stage in axial spondylarthritis: Results from the german spondyloarthritis inception cohort. <i>Arthritis and Rheumatism</i> , 2009, 60, 717-727.	6.7	605
9	Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2013, 382, 1705-1713.	6.3	518
10	Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial. <i>Arthritis and Rheumatism</i> , 2008, 58, 3402-3412.	6.7	512
11	Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor β monoclonal antibody infliximab. <i>Arthritis and Rheumatism</i> , 2000, 43, 1346-1352.	6.7	506
12	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.5	484
13	Inflammatory back pain in ankylosing spondylitis: A reassessment of the clinical history for application as classification and diagnostic criteria. <i>Arthritis and Rheumatism</i> , 2006, 54, 569-578.	6.7	472
14	Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 815-822.	0.5	449
15	The challenge of diagnosis and classification in early ankylosing spondylitis: Do we need new criteria?. <i>Arthritis and Rheumatism</i> , 2005, 52, 1000-1008.	6.7	448
16	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 6-16.	0.5	397
17	Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 1388-1398.	6.7	384
18	Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1958-1963.	0.5	383

#	ARTICLE	IF	CITATIONS
19	2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 905-908.	0.5	365
20	Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. <i>Arthritis and Rheumatism</i> , 1994, 37, 1039-1045.	6.7	320
21	Efficacy of adalimumab in the treatment of axial spondylarthritits without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. <i>Arthritis and Rheumatism</i> , 2008, 58, 1981-1991.	6.7	293
22	Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1369-1374.	0.5	293
23	Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1616-1622.	0.5	286
24	Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2009, 60, 3257-3262.	6.7	282
25	Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1295-1302.	0.5	275
26	Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. <i>Arthritis Research and Therapy</i> , 2011, 13, R95.	1.6	267
27	Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. <i>Lancet. The</i> , 2018, 392, 2441-2451.	6.3	251
28	Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 710-715.	0.5	238
29	Three Multicenter, Randomized, Double-blind, Placebo-controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 258-270.	2.9	237
30	Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 817-823.	0.5	236
31	Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. <i>Arthritis Research</i> , 2005, 7, R439.	2.0	233
32	Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. <i>Lancet. The</i> , 2019, 394, 2108-2117.	6.3	223
33	Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1278-1288.	0.5	218
34	Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1070-1077.	0.5	213
35	The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. <i>Arthritis Research and Therapy</i> , 2008, 10, R104.	1.6	211
36	ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 249-251.	0.5	208

#	ARTICLE	IF	CITATIONS
37	Critical appraisal of assessment of structural damage in ankylosing spondylitis: Implications for treatment outcomes. <i>Arthritis and Rheumatism</i> , 2008, 58, 649-656.	6.7	206
38	High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 572-574.	0.5	201
39	Concepts and epidemiology of spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006, 20, 401-417.	1.4	196
40	Effectiveness, Safety, and Predictors of Good Clinical Response in 1250 Patients Treated with Adalimumab for Active Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2009, 36, 801-808.	1.0	189
41	Symptomatic Efficacy of Etanercept and Its Effects on Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. <i>Arthritis and Rheumatology</i> , 2014, 66, 2091-2102.	2.9	185
42	Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 95-100.	0.5	181
43	Efficacy of TNF± blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1241-1248.	0.5	176
44	Pathogenesis of spondylarthropathies. <i>Arthritis and Rheumatism</i> , 1995, 38, 1547-1554.	6.7	175
45	Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2006, 54, 2845-2851.	6.7	172
46	MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1550-1558.	0.5	171
47	Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1438-1443.	0.5	163
48	Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. <i>Arthritis and Rheumatism</i> , 1997, 40, 1788-1797.	6.7	158
49	Predicting the outcome of ankylosing spondylitis therapy. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 973-981.	0.5	158
50	Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. <i>Arthritis Research and Therapy</i> , 2006, 8, R143.	1.6	153
51	Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1479-1484.	0.5	153
52	Review: Nonradiographic axial spondyloarthritis: New definition of an old disease?. <i>Arthritis and Rheumatism</i> , 2013, 65, 543-551.	6.7	153
53	Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. <i>Arthritis and Rheumatism</i> , 2006, 54, 678-681.	6.7	150
54	No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: A three-month, multicenter, double-blind, randomized, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 1999, 42, 1386-1396.	6.7	149

#	ARTICLE	IF	CITATIONS
55	Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: Evaluation of the bone-cartilage interface and subchondral bone marrow. <i>Arthritis and Rheumatism</i> , 2006, 54, 1805-1813.	6.7	139
56	Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. <i>Lancet</i> , The, 2020, 395, 53-64.	6.3	138
57	Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 571-592.	0.5	137
58	Comparison of MRI with radiography for detecting structural lesions of the sacroiliac joint using CT as standard of reference: results from the SIMACT study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1502-1508.	0.5	136
59	Axial spondyloarthritis. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15013.	18.1	135
60	Low secretion of tumor necrosis factor γ , but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. <i>Arthritis and Rheumatism</i> , 1999, 42, 2039-2044.	6.7	133
61	Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1051-1057.	0.5	128
62	ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1646-1653.	0.5	127
63	Identification of HLA-B27-Restricted Peptides from the <i>Chlamydia trachomatis</i> Proteome with Possible Relevance to HLA-B27-Associated Diseases. <i>Journal of Immunology</i> , 2001, 167, 4738-4746.	0.4	125
64	In Situ Analysis of Interleukin-23 and Interleukin-12 Positive Cells in the Spine of Patients With Ankylosing Spondylitis. <i>Arthritis and Rheumatism</i> , 2013, 65, 1522-1529.	6.7	121
65	Diagnosing reactive arthritis: Role of clinical setting in the value of serologic and microbiologic assays. <i>Arthritis and Rheumatism</i> , 2002, 46, 319-327.	6.7	120
66	Evaluation of 2 Screening Strategies for Early Identification of Patients with Axial Spondyloarthritis in Primary Care. <i>Journal of Rheumatology</i> , 2011, 38, 2452-2460.	1.0	117
67	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii2-ii34.	0.5	114
68	The burden of non-radiographic axial spondyloarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 556-562.	1.6	112
69	Referral strategies for early diagnosis of axial spondyloarthritis. <i>Nature Reviews Rheumatology</i> , 2012, 8, 262-268.	3.5	111
70	Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 967-973.	0.5	109
71	HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2005, 52, 892-901.	6.7	108
72	Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years-early clinical response predicts long-term outcome. <i>Rheumatology</i> , 2011, 50, 1690-1699.	0.9	105

#	ARTICLE	IF	CITATIONS
73	New evidence on the management of spondyloarthritis. <i>Nature Reviews Rheumatology</i> , 2016, 12, 282-295.	3.5	104
74	High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GERman SPondyloarthritis Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2114-2118.	0.5	103
75	Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. <i>Journal of Rheumatology</i> , 2002, 29, 118-22.	1.0	103
76	Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 823-825.	0.5	100
77	Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. <i>Rheumatology</i> , 2019, 58, 1634-1638.	0.9	100
78	Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1483-1487.	0.5	99
79	Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. <i>Arthritis and Rheumatism</i> , 2008, 59, 1270-1278.	6.7	98
80	Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype?. <i>Arthritis and Rheumatism</i> , 2013, 65, 12-20.	6.7	96
81	Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1621-1627.	0.5	93
82	Characterization of the synovial T cell response to various recombinant <i>Yersinia enterocolitica</i> -triggered reactive arthritis: Heat-shock protein 60 drives a major immune response. <i>Arthritis and Rheumatism</i> , 1998, 41, 315-326.	6.7	89
83	Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1212-1215.	0.5	82
84	The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administration's Comments and Concerns. <i>Arthritis and Rheumatology</i> , 2014, 66, 2649-2656.	2.9	81
85	Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1328-1335.	0.5	81
86	Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. <i>Lancet, The</i> , 2018, 392, 134-144.	6.3	81
87	Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 700-706.	0.5	80
88	Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. <i>Rheumatology</i> , 2017, 56, 1498-1509.	0.9	78
89	The IL-23/IL-17 pathway as a therapeutic target in axial spondyloarthritis. <i>Nature Reviews Rheumatology</i> , 2019, 15, 747-757.	3.5	78
90	Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis. <i>RMD Open</i> , 2019, 5, e001108.	1.8	77

#	ARTICLE	IF	CITATIONS
91	Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 176-185.	0.5	76
92	Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. <i>Arthritis and Rheumatism</i> , 2000, 43, 2834-2842.	6.7	75
93	Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1746-1748.	0.5	71
94	Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2006, 33, 86-90.	1.0	71
95	Improved detection of erosions in the sacroiliac joints on MRI with volumetric interpolated breath-hold examination (VIBE): results from the SIMACT study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1585-1589.	0.5	69
96	Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. <i>Arthritis Research and Therapy</i> , 2009, 11, R124.	1.6	68
97	Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GERman SPondyloarthritis Inception Cohort (GESPIC). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1430-1432.	0.5	67
98	Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 914-923.	2.9	67
99	Serum Adipokine Levels in Patients With Ankylosing Spondylitis and Their Relationship to Clinical Parameters and Radiographic Spinal Progression. <i>Arthritis and Rheumatology</i> , 2015, 67, 678-685.	2.9	67
100	Spinal Inflammation in the Absence of Sacroiliac Joint Inflammation on Magnetic Resonance Imaging in Patients With Active Nonradiographic Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 667-673.	2.9	65
101	Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. <i>Journal of Rheumatology</i> , 2004, 31, 531-8.	1.0	65
102	Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. <i>RMD Open</i> , 2021, 7, e001450.	1.8	64
103	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 88-93.	0.5	63
104	Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2137-2143.	0.5	62
105	The frequency of non-radiographic axial spondyloarthritis in relation to symptom duration in patients referred because of chronic back pain: results from the Berlin early spondyloarthritis clinic. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1998-2001.	0.5	60
106	Similarities and differences between nonradiographic and radiographic axial spondyloarthritis. <i>Current Opinion in Rheumatology</i> , 2014, 26, 377-383.	2.0	58
107	Mechanism of New Bone Formation in Axial Spondyloarthritis. <i>Current Rheumatology Reports</i> , 2017, 19, 55.	2.1	58
108	Multispecific CD4+ T Cell Response to a Single 12-mer Epitope of the Immunodominant Heat-Shock Protein 60 of <i>Yersinia enterocolitica</i> in <i>Yersinia</i> -Triggered Reactive Arthritis: Overlap with the B27-Restricted CD8 Epitope, Functional Properties, and Epitope Presentation by Multiple DR Alleles. <i>Journal of Immunology</i> , 2000, 164, 1529-1537.	0.4	55

#	ARTICLE	IF	CITATIONS
109	Magnetic Resonance Imaging Compared to Conventional Radiographs for Detection of Chronic Structural Changes in Sacroiliac Joints in Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1557-1565.	1.0	55
110	Histomorphologic and Histomorphometric Characteristics of Zygapophyseal Joint Remodeling in Ankylosing Spondylitis. <i>Arthritis and Rheumatology</i> , 2014, 66, 1745-1754.	2.9	54
111	Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. <i>Arthritis Research and Therapy</i> , 2008, 10, R125.	1.6	53
112	Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1034-1042.	0.5	53
113	Clinical and imaging characteristics of osteitis condensans ilii as compared with axial spondyloarthritis. <i>Rheumatology</i> , 2020, 59, 3798-3806.	0.9	52
114	Radiographic progression in ankylosing spondylitis/axial spondyloarthritis. <i>Current Opinion in Rheumatology</i> , 2012, 24, 363-369.	2.0	48
115	Developments in therapies for spondyloarthritis. <i>Nature Reviews Rheumatology</i> , 2012, 8, 280-287.	3.5	47
116	One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 305-306.	0.5	47
117	Granulation Tissue Eroding the Subchondral Bone Also Promotes New Bone Formation in Ankylosing Spondylitis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2456-2465.	2.9	47
118	Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2007, 34, 510-5.	1.0	47
119	Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care. <i>RMD Open</i> , 2018, 4, e000825.	1.8	45
120	Diverse effects of infliximab and etanercept on T lymphocytes. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 34, 23-27.	1.6	44
121	Synovial and Peripheral Blood CD4+FoxP3+ T Cells in Spondyloarthritis. <i>Journal of Rheumatology</i> , 2011, 38, 2445-2451.	1.0	44
122	Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1017-1024.	0.5	44
123	Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility. <i>Rheumatology</i> , 2021, 60, 4778-4789.	0.9	44
124	Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. <i>Arthritis Research and Therapy</i> , 2017, 19, 240.	1.6	43
125	Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1515-1523.	0.5	43
126	Course of Magnetic Resonance Imagingâ€“Detected Inflammation and Structural Lesions in the Sacroiliac Joints of Patients in the Randomized, Doubleâ€“Blind, Placeboâ€“Controlled Danish Multicenter Study of Adalimumab in Spondyloarthritis, as Assessed by the Berlin and Spondyloarthritis Research Consortium of Canada Methods. <i>Arthritis and Rheumatology</i> , 2016, 68, 418-429.	2.9	42

#	ARTICLE	IF	CITATIONS
127	Pathogenesis of reactive arthritis. <i>Current Rheumatology Reports</i> , 2001, 3, 412-418.	2.1	41
128	Developments in the scientific and clinical understanding of the spondyloarthritides. <i>Arthritis Research and Therapy</i> , 2009, 11, 208.	1.6	41
129	Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study. <i>RMD Open</i> , 2019, 5, e000585.	1.8	41
130	Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab. <i>Rheumatology</i> , 2015, 54, 1210-1219.	0.9	40
131	Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial. <i>Arthritis Research and Therapy</i> , 2017, 19, 140.	1.6	40
132	Identification of Novel Human Aggrecan T Cell Epitopes in HLA-B27 Transgenic Mice Associated with Spondyloarthropathy. <i>Journal of Immunology</i> , 2004, 173, 4859-4866.	0.4	39
133	Immunohistochemical Analysis of Osteoblasts in Zygapophyseal Joints of Patients with Ankylosing Spondylitis Reveal Repair Mechanisms Similar to Osteoarthritis. <i>Journal of Rheumatology</i> , 2010, 37, 823-828.	1.0	39
134	Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab. <i>Journal of Rheumatology</i> , 2017, 44, 599-608.	1.0	39
135	Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF- α Inhibitors for Up to 10 Years. <i>Journal of Rheumatology</i> , 2016, 43, 2142-2148.	1.0	38
136	Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension. <i>Arthritis and Rheumatology</i> , 2022, 74, 70-80.	2.9	38
137	Classification and Diagnosis of Axial Spondyloarthritis – What Is the Clinically Relevant Difference?. <i>Journal of Rheumatology</i> , 2015, 42, 31-38.	1.0	37
138	Functional relevance of radiographic spinal progression in axial spondyloarthritis: results from the GERman SPondyloarthritis Inception Cohort. <i>Rheumatology</i> , 2018, 57, 703-711.	0.9	37
139	Deep learning for detection of radiographic sacroiliitis: achieving expert-level performance. <i>Arthritis Research and Therapy</i> , 2021, 23, 106.	1.6	37
140	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 872-878.	0.5	36
141	The Evolutionarily Conserved Ribosomal Protein L23 and the Cationic Urease β -Subunit of <i>Yersinia enterocolitica</i> O:3 Belong to the Immunodominant Antigens in <i>Yersinia</i> -Triggered Reactive Arthritis: Implications for Autoimmunity. <i>Molecular Medicine</i> , 1994, 1, 44-55.	1.9	35
142	Comparison of an online self-referral tool with a physician-based referral strategy for early recognition of patients with a high probability of axial spa. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1015-1021.	1.6	35
143	Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis – 3-Year data of the ESTHER trial. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 404-410.	1.6	33
144	Age- and Sex-dependent Frequency of Fat Metaplasia and Other Structural Changes of the Sacroiliac Joints in Patients without Axial Spondyloarthritis: A Retrospective, Cross-sectional MRI Study. <i>Journal of Rheumatology</i> , 2018, 45, 915-921.	1.0	33

#	ARTICLE	IF	CITATIONS
145	Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers. <i>Arthritis Research and Therapy</i> , 2014, 16, R35.	1.6	32
146	Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 61.	1.6	32
147	Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort. <i>Journal of Rheumatology</i> , 2018, 45, 506-512.	1.0	31
148	In vivo pre-activation of monocytes in patients with axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 179.	1.6	30
149	Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study. <i>RMD Open</i> , 2019, 5, e000917.	1.8	30
150	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110579.	1.2	30
151	How to define remission in ankylosing spondylitis?. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, i93-i95.	0.5	29
152	Relationship of bone mineral density with disease activity and functional ability in patients with ankylosing spondylitis: a cross-sectional study. <i>Rheumatology International</i> , 2012, 32, 2801-2808.	1.5	29
153	Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time. <i>Rheumatology</i> , 2017, 56, 1162-1166.	0.9	29
154	Systematic review of clinical, humanistic, and economic outcome comparisons between radiographic and non-radiographic axial spondyloarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 746-753.	1.6	29
155	Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort. <i>Arthritis and Rheumatology</i> , 2015, 67, 2369-2375.	2.9	28
156	Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study. <i>Arthritis Care and Research</i> , 2017, 69, 1590-1598.	1.5	28
157	Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis. <i>Rheumatology</i> , 2019, 58, 1556-1564.	0.9	28
158	Consistently Good Clinical Response in Patients with Early Axial Spondyloarthritis After 3 Years of Continuous Treatment with Etanercept: Longterm Data of the ESTHER Trial. <i>Journal of Rheumatology</i> , 2014, 41, 2034-2040.	1.0	27
159	Cartilage in facet joints of patients with ankylosing spondylitis (AS) shows signs of cartilage degeneration rather than chondrocyte hypertrophy: implications for joint remodeling in AS. <i>Arthritis Research and Therapy</i> , 2015, 17, 170.	1.6	27
160	Early diagnosis of spondyloarthritis. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 536-545.	3.2	26
161	Spondyloarthritis at the crossroads of imaging, pathology, and structural damage in the era of biologics. <i>Current Rheumatology Reports</i> , 2008, 10, 356-363.	2.1	25
162	Erosions and Fatty Lesions of Sacroiliac Joints in Patients with Axial Spondyloarthritis: Evaluation of Different MRI Techniques and Two Scoring Methods. <i>Journal of Rheumatology</i> , 2014, 41, 473-480.	1.0	25

#	ARTICLE	IF	CITATIONS
163	What is the best treatment target in axial spondyloarthritis: tumour necrosis factor $\hat{\pm}$, interleukin 17, or both?. <i>Rheumatology</i> , 2018, 57, 1145-1150.	0.9	25
164	Five-year follow-up of radiographic sacroiliitis: progression as well as improvement?. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1262-1263.	0.5	24
165	Course of patients with juvenile spondyloarthritis during 4â€¦years of observation, juvenile part of GESPIC. <i>RMD Open</i> , 2017, 3, e000366.	1.8	24
166	Current Unmet Needs in Spondyloarthritis. <i>Current Rheumatology Reports</i> , 2019, 21, 43.	2.1	24
167	Disease mechanisms in reactive arthritis. <i>Current Rheumatology Reports</i> , 2004, 6, 110-116.	2.1	23
168	Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?. <i>Rheumatology</i> , 2019, 58, 1649-1654.	0.9	23
169	MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1243-1251.	0.5	22
170	Diagnosing early ankylosing spondylitis. <i>Current Rheumatology Reports</i> , 2007, 9, 367-374.	2.1	21
171	HLA-B27-restricted antigen presentation by human chondrocytes to CD8+ T cells: Potential contribution to local immunopathologic processes in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2009, 60, 1635-1646.	6.7	21
172	Classification, Diagnosis, and Referral of Patients with Axial Spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 477-485.	0.8	21
173	New treatment targets for axial spondyloarthritis: Table 1. <i>Rheumatology</i> , 2016, 55, ii38-ii42.	0.9	21
174	Peripheral spondyloarthritis: Concept, diagnosis and treatment. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 357-368.	1.4	21
175	Progression of Structural Damage in the Sacroiliac Joints in Patients With Early Axial Spondyloarthritis During Long-Term Anti-Tumor Necrosis Factor Treatment: Six-Year Results of Continuous Treatment With Etanercept. <i>Arthritis and Rheumatology</i> , 2019, 71, 722-728.	2.9	21
176	Can structural damage be prevented in ankylosing spondylitis?. <i>Current Opinion in Rheumatology</i> , 2009, 21, 335-339.	2.0	20
177	Impaired Peripheral Th1 CD4+ T Cell Response to Escherichia coli Proteins in Patients with Crohn's Disease and Ankylosing Spondylitis. <i>Journal of Clinical Immunology</i> , 2011, 31, 998-1009.	2.0	20
178	Treatment of Axial Spondyloarthritis: What Does the Future Hold?. <i>Current Rheumatology Reports</i> , 2020, 22, 47.	2.1	20
179	Identification of HLA-B27-restricted peptides in reactive arthritis and other spondyloarthropathies. <i>Rheumatic Disease Clinics of North America</i> , 2003, 29, 595-611.	0.8	19
180	Differential synovial Th1 cell reactivity towards Escherichia coli antigens in patients with ankylosing spondylitis and rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1573-1576.	0.5	19

#	ARTICLE	IF	CITATIONS
181	Synovial cell production of IL-26 induces bone mineralization in spondyloarthritis. <i>Journal of Molecular Medicine</i> , 2017, 95, 779-787.	1.7	19
182	Adalimumab for the treatment of ankylosing spondylitis. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 831-838.	0.9	18
183	Relation of HLA-B27, Tumor Necrosis Factor- α Promoter Gene Polymorphisms, and T Cell Cytokine Production in Ankylosing Spondylitis – A Comprehensive Genotype-Phenotype Analysis from an Observational Cohort. <i>Journal of Rheumatology</i> , 2011, 38, 2436-2441.	1.0	18
184	Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial. <i>Rheumatology</i> , 2015, 54, 257-261.	0.9	18
185	How Important is Early Therapy in Axial Spondyloarthritis?. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 635-642.	0.8	17
186	Vertebral Erosions Associated with Spinal Inflammation in Patients with Ankylosing Spondylitis Identified by Magnetic Resonance Imaging: Changes After 2 Years of Tumor Necrosis Factor Inhibitor Therapy. <i>Journal of Rheumatology</i> , 2013, 40, 1891-1896.	1.0	17
187	Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics. <i>Rheumatology</i> , 2016, 55, 1946-1953.	0.9	17
188	Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) – an open-label randomized controlled multicenter trial. <i>BMJ Open</i> , 2017, 7, e014591.	0.8	17
189	The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2097261.	1.2	17
190	Do ethnicity, degree of family relationship, and the spondyloarthritis subtype in affected relatives influence the association between a positive family history for spondyloarthritis and HLA-B27 carriership? Results from the worldwide ASAS cohort. <i>Arthritis Research and Therapy</i> , 2018, 20, 166.	1.6	16
191	Detection of Sacroiliitis by Short-tau Inversion Recovery and T2-weighted Turbo Spin Echo Sequences: Results from the SIMACT Study. <i>Journal of Rheumatology</i> , 2019, 46, 376-383.	1.0	16
192	The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study. <i>Arthritis Research and Therapy</i> , 2020, 22, 210.	1.6	16
193	Genetic diagnostic profiling in axial spondyloarthritis: a real world study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 229-233.	0.4	16
194	Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results. <i>Rheumatology</i> , 2022, 61, 3299-3308.	0.9	16
195	How to screen for axial spondyloarthritis in primary care?. <i>Current Opinion in Rheumatology</i> , 2012, 24, 359-362.	2.0	15
196	Brief Report: Course of Active Inflammatory and Fatty Lesions in Patients With Early Axial Spondyloarthritis Treated With Infliximab Plus Naproxen as Compared to Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial. <i>Arthritis and Rheumatology</i> , 2016, 68, 1899-1903.	2.9	15
197	Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?. <i>Current Opinion in Rheumatology</i> , 2010, 22, 388-392.	2.0	14
198	Diagnostic delay in axial spondyloarthritis – a past or current problem?. <i>Current Opinion in Rheumatology</i> , 2021, 33, 307-312.	2.0	14

#	ARTICLE	IF	CITATIONS
199	Anti-TNF agents for the treatment of spondyloarthropathies. <i>Expert Opinion on Emerging Drugs</i> , 2002, 7, 235-246.	1.0	13
200	Challenges of diagnosis and management of axial spondyloarthritis in North Africa and the Middle East: An expert consensus. <i>Journal of International Medical Research</i> , 2016, 44, 216-230.	0.4	13
201	Homologous high-throughput expression and purification of highly conserved E coli proteins. <i>Microbial Cell Factories</i> , 2007, 6, 18.	1.9	12
202	Inflammation, new bone formation and treatment options in axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1439-1441.	0.5	12
203	Fluoroscopy-guided application of corticosteroids for local control of manubriosternal joint pain in patients with spondyloarthropathies. <i>Clinical Rheumatology</i> , 2004, 23, 481-484.	1.0	11
204	Current Controversies in Spondyloarthritis: SPARTAN. <i>Journal of Rheumatology</i> , 2010, 37, 2617-2623.	1.0	11
205	An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus. <i>Arthritis Research and Therapy</i> , 2018, 20, 191.	1.6	11
206	Performance of the Ankylosing Spondylitis Disease Activity Score based on a quick quantitative C-reactive protein assay in patients with axial spondyloarthritis. <i>Joint Bone Spine</i> , 2020, 87, 69-73.	0.8	11
207	What amount of structural damage defines sacroiliitis: a CT study. <i>RMD Open</i> , 2022, 8, e001939.	1.8	11
208	Treatment With Tumor Necrosis Factor Inhibitors Is Associated With a Time-Shifted Retardation of Radiographic Sacroiliitis Progression in Patients With Axial Spondyloarthritis: 10-Year Results From the German Spondyloarthritis Inception Cohort. <i>Arthritis and Rheumatology</i> , 2022, 74, 1515-1523.	2.9	11
209	Reactive Spondyloarthritis: Epidemiology, Clinical Features, and Treatment. , 2006, , 53-64.		10
210	Burden of illness associated with non-radiographic axial spondyloarthritis: a multiperspective European cross-sectional observational study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 975-983.	0.4	10
211	Identification of immunodominant CD4+ T cell epitopes in patients with Yersinia-induced reactive arthritis by cytometric cytokine secretion assay. <i>Arthritis and Rheumatism</i> , 2006, 54, 3583-3590.	6.7	8
212	Investigation of involved tissue in axial spondyloarthritis – what have we learnt from immunohistochemical studies?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 715-719.	1.4	8
213	The safety of celecoxib in ankylosing spondylitis treatment. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 401-409.	1.0	7
214	Relevance of osteoproliferation as an outcome parameter in ankylosing spondylitis. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 578-579.	3.2	7
215	Diagnosing axial spondyloarthritis: estimation of the disease probability in patients with a priori different likelihoods of the diagnosis. <i>Rheumatology</i> , 2021, 60, 5098-5104.	0.9	7
216	Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1252-1259.	0.5	7

#	ARTICLE	IF	CITATIONS
217	New insights into therapyâ€”TNF blockade and beyond. <i>Nature Reviews Rheumatology</i> , 2011, 7, 78-80.	3.5	6
218	Disease activity in ankylosing spondylitis: the global therapeutic target. <i>Annals of the Rheumatic Diseases</i> , 2017, 77, annrheumdis-2017-212363.	0.5	6
219	Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2098770.	1.2	6
220	Treatment Challenges in Axial Spondylarthritis and Future Directions. <i>Current Rheumatology Reports</i> , 2013, 15, 356.	2.1	5
221	Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2. <i>RMD Open</i> , 2018, 4, e000566.	1.8	5
222	Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study. <i>RMD Open</i> , 2021, 7, e001728.	1.8	5
223	IgA antibodies against CD74 are associated with structural damage in the axial skeleton in patients with axial spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1127-1131.	0.4	5
224	Ankylosing spondylitis self-help organisations â€”Do members differ from non-members?. <i>Joint Bone Spine</i> , 2016, 83, 295-300.	0.8	4
225	What is the optimal target for a T2T approach in axial spondyloarthritis?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, annrheumdis-2021-220603.	0.5	4
226	Clinicianâ€™s Manual on Axial Spondyloarthritis. , 2014, , .		3
227	Reply. <i>Arthritis and Rheumatology</i> , 2015, 67, 2793-2794.	2.9	3
228	Analysis of Bone Samples from Patients with Spondyloarthritisâ€”Identifying Causes of New Bone Formation in Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2015, 42, 561-563.	1.0	3
229	Assessment of radiographic sacroiliitis in anteroposterior lumbar vs conventional pelvic radiographs in axial spondyloarthritis. <i>Rheumatology</i> , 2021, 60, 269-276.	0.9	3
230	Twenty years of clinical trials in axial spondyloarthritis: what can we learn for the future?. <i>Current Opinion in Rheumatology</i> , 2021, 33, 363-369.	2.0	3
231	Predictive value of C-reactive protein for radiographic spinal progression in axial spondyloarthritis in dependence on genetic determinants of fibrin clot formation and fibrinolysis. <i>RMD Open</i> , 2021, 7, e001751.	1.8	3
232	Diagnosis of Axial Spondyloarthritis. , 2014, , 31-45.		3
233	Defining an optimal referral strategy for patients with a suspicion of axial spondyloarthritis: what is really important? Response to: â€”Evaluating the ASAS recommendations for early referral of axial spondyloarthritis in patients with chronic low back pain; is one parameter present sufficient for primary care practice?â€” by van Hoeven <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> . 2015, 74, 1-1.	0.5	3
234	Geographical prevalence of family history in patients with axial spondyloarthritis and its association with HLA-B27 in the ASAS-PerSpA study. <i>RMD Open</i> , 2022, 8, e002174.	1.8	3

#	ARTICLE	IF	CITATIONS
235	Response to H Zeidler's comments on the INFAST study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e19-e19.	0.5	2
236	Incorporation of the anteroposterior lumbar radiographs in the modified Stoke Ankylosing Spondylitis Spine Score improves detection of radiographic spinal progression in axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 126.	1.6	2
237	Overview of Axial Spondyloarthritis. , 2014, , 5-16.		2
238	Management of ankylosing spondylitis. , 2011, , 1157-1177.e3.		2
239	Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. , 0, .		2
240	Management of Axial Spondyloarthritis. , 2014, , 59-96.		2
241	Infliximab therapy for patients with ankylosing spondylitis: on-demand or continuous treatment?. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 398-399.	3.2	1
242	215.â€fSustained Clinical Remission in Patients with Non-Radiographic Axial Spondyloarthritis after Two Years of Adalimumab Treatment. <i>Rheumatology</i> , 2014, 53, i140-i140.	0.9	1
243	THU0365â€...THE IMPACT OF UVEITIS, PSORIASIS AND INFLAMMATORY BOWEL DISEASE ON MUSCULOSKELETAL DISEASE ACTIVITY AND FUNCTION IN AXIAL SPONDYLOARTHRITIS: A POPULATION-BASED ANALYSIS OF INSURANCE CLAIMS LINKED TO PATIENT SURVEY DATA. , 2019, , .		1
244	Relation of Î±2-Antiplasmin Genotype and Genetic Determinants of Fibrinogen Synthesis and Fibrin Clot Formation with Vascular Endothelial Growth Factor Level in Axial Spondyloarthritis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9383.	1.8	1
245	Spondyloarthritides. , 2020, , 691-701.		1
246	Management of ankylosing spondylitis/axial spondyloarthritis. , 2015, , 970-985.		1
247	Preface. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, xvii-xxi.	0.8	0
248	A4.11â€...Baseline Elevated Serum Levels of Calprotectin as Independent Marker for Radiographic Spinal Progression in Ankylosing Spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A28.1-A28.	0.5	0
249	I59.â€fNew Biologic Treatments for Ankylosing Spondylitis. <i>Rheumatology</i> , 2014, 53, i13-i13.	0.9	0
250	Associations de patients atteints de spondylarthrite ankylosanteÂ€Âquelles diffÃ©rences entre membres et non-membresÂ?. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017, 84, 231-237.	0.0	0
251	Response to â€Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happierâ€™ by Alunno <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e55-e55.	0.5	0
252	Treatment Guidelines for Axial Spondyloarthritis. , 2019, , 243-258.		0

#	ARTICLE	IF	CITATIONS
253	SAT0347â€¦...COMORBID CONDITIONS ARE ASSOCIATED WITH HIGHER DISEASE ACTIVITY AND WORSE FUNCTIONAL STATUS IN AXIAL SPONDYLOARTHRITIS: A POPULATION-BASED ANALYSIS OF INSURANCE CLAIMS LINKED TO PATIENT SURVEY DATA. , 2019, , .		0
254	THU0366â€¦...MAGNETIC RESONANCE IMAGING IN COMPARISON WITH CONVENTIONAL RADIOGRAPHY FOR DETECTION OF STRUCTURAL CHANGES TYPICAL FOR SPA â€œ“ DATA FROM THE ASSESSMENT OF SPONDYLOARTHRITIS INTERNATIONAL SOCIETY (ASAS) COHORT. , 2019, , .		0
255	SAT0305â€¦...ASSOCIATION OF SKIN PSORIASIS WITH CLINICAL AND RADIOGRAPHIC CHARACTERISTICS IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE GERMAN SPONDYLOARTHRITIS INCEPTION COHORT. , 2019, , .		0
256	Pathogenesis of Reactive Arthritis. , 2007, , 181-187.		0
257	Socioeconomic aspects of ankylosing spondylitis. , 2009, , 73-73.		0
258	Clinical Manifestations of Axial Spondyloarthritis. , 2014, , 17-29.		0
259	Reply to the editorial: Can we currently and confidently assess the true burden of illness due to non-radiographic axial spondyloarthritis? by S. van der Linden and M.A. Khan. Clinical and Experimental Rheumatology, 2016, 34, 1121.	0.4	0